Skip to main content
Erschienen in: Cancer and Metastasis Reviews 2/2011

01.06.2011 | NON-THEMATIC REVIEW

True local recurrences do not metastasize

verfasst von: Dieter Hölzel, Rebecca T. Emeny, Jutta Engel

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Generally, the limits of local tumor control are in part connected with the term “field cancerization” and are known from oral, lung, prostate, or mammary cancer. With the example of breast cancer (BC), the problem of ipsilateral breast tumor recurrences (IBTR) after breast-conserving surgery will be reviewed. Three types of local recurrences are distinguished: true recurrences, new primaries, or residual tumors. Good data for BC allow the description of the time-dependent risk of these three types, relative to the diagnosis of the primary tumor, because the time of initiation and the growth duration of the IBTR can be estimated. Two hypotheses explain the data: first, local recurrences may be initiated years before the diagnosis of a primary tumor (PT) and can then appear as multifocal PT at diagnosis, and second, true local recurrences probably do not metastasize. The generalizability of these hypotheses for other tumors will be discussed.
Literatur
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366(9503), 2087–2106. Early Breast Cancer Trialists’ Collaborative Group. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366(9503), 2087–2106.
3.
Zurück zum Zitat Freedman, G. M., Anderson, P. R., Hanlon, A. L., Eisenberg, D. F., & Nicolaou, N. (2005). Pattern of local recurrence after conservative surgery and whole-breast irradiation. International Journal of Radiation Oncology, Biology, Physics, 61(5), 1328–1336.PubMedCrossRef Freedman, G. M., Anderson, P. R., Hanlon, A. L., Eisenberg, D. F., & Nicolaou, N. (2005). Pattern of local recurrence after conservative surgery and whole-breast irradiation. International Journal of Radiation Oncology, Biology, Physics, 61(5), 1328–1336.PubMedCrossRef
4.
Zurück zum Zitat Engel, J., Eckel, R., Aydemir, U., Aydemir, S., Kerr, J., Schlesinger-Raab, A., et al. (2003). Determinants and prognoses of locoregional and distant progression in breast cancer. International Journal of Radiation Oncology, Biology, Physics, 55(5), 1186–1195. doi:S0360301602044760.PubMedCrossRef Engel, J., Eckel, R., Aydemir, U., Aydemir, S., Kerr, J., Schlesinger-Raab, A., et al. (2003). Determinants and prognoses of locoregional and distant progression in breast cancer. International Journal of Radiation Oncology, Biology, Physics, 55(5), 1186–1195. doi:S036030160204476​0.PubMedCrossRef
5.
Zurück zum Zitat Voogd, A. C., van Oost, F. J., Rutgers, E. J., Elkhuizen, P. H., van Geel, A. N., Scheijmans, L. J., et al. (2005). Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. European Journal of Cancer, 41(17), 2637–2644.PubMedCrossRef Voogd, A. C., van Oost, F. J., Rutgers, E. J., Elkhuizen, P. H., van Geel, A. N., Scheijmans, L. J., et al. (2005). Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. European Journal of Cancer, 41(17), 2637–2644.PubMedCrossRef
8.
Zurück zum Zitat Recht, A., Silver, B., Schnitt, S., Connolly, J., Hellman, S., & Harris, J. R. (1985). Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. International Journal of Radiation Oncology, Biology, Physics, 11(7), 1271–1276.PubMedCrossRef Recht, A., Silver, B., Schnitt, S., Connolly, J., Hellman, S., & Harris, J. R. (1985). Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. International Journal of Radiation Oncology, Biology, Physics, 11(7), 1271–1276.PubMedCrossRef
9.
Zurück zum Zitat Haffty, B. G., Carter, D., Flynn, S. D., Fischer, D. B., Brash, D. E., Simons, J., et al. (1993). Local recurrence versus new primary: Clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. International Journal of Radiation Oncology, Biology, Physics, 27(3), 575–583.PubMedCrossRef Haffty, B. G., Carter, D., Flynn, S. D., Fischer, D. B., Brash, D. E., Simons, J., et al. (1993). Local recurrence versus new primary: Clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. International Journal of Radiation Oncology, Biology, Physics, 27(3), 575–583.PubMedCrossRef
10.
Zurück zum Zitat Komoike, Y., Akiyama, F., Iino, Y., Ikeda, T., Tanaka-Akashi, S., Ohsumi, S., et al. (2005). Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer, 12(2), 104–111.PubMedCrossRef Komoike, Y., Akiyama, F., Iino, Y., Ikeda, T., Tanaka-Akashi, S., Ohsumi, S., et al. (2005). Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer, 12(2), 104–111.PubMedCrossRef
11.
Zurück zum Zitat Smith, T. E., Lee, D., Turner, B. C., Carter, D., & Haffty, B. G. (2000). True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. International Journal of Radiation Oncology, Biology, Physics, 48(5), 1281–1289.PubMedCrossRef Smith, T. E., Lee, D., Turner, B. C., Carter, D., & Haffty, B. G. (2000). True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. International Journal of Radiation Oncology, Biology, Physics, 48(5), 1281–1289.PubMedCrossRef
12.
Zurück zum Zitat Goldstein, N. S., Vicini, F. A., Hunter, S., Odish, E., Forbes, S., & Kestin, L. L. (2005). Molecular clonality relationships in initial carcinomas, ipsilateral breast failures, and distant metastases in patients treated with breast-conserving therapy: Evidence suggesting that some distant metastases are derived from ipsilateral breast failures and that metastases can metastasize. American Journal of Clinical Pathology, 124(1), 49–57. doi:10.1309/2GAMH08G25JXVWHQ.PubMedCrossRef Goldstein, N. S., Vicini, F. A., Hunter, S., Odish, E., Forbes, S., & Kestin, L. L. (2005). Molecular clonality relationships in initial carcinomas, ipsilateral breast failures, and distant metastases in patients treated with breast-conserving therapy: Evidence suggesting that some distant metastases are derived from ipsilateral breast failures and that metastases can metastasize. American Journal of Clinical Pathology, 124(1), 49–57. doi:10.​1309/​2GAMH08G25JXVWHQ​.PubMedCrossRef
13.
Zurück zum Zitat Noguchi, S., Aihara, T., Koyama, H., Motomura, K., Inaji, H., & Imaoka, S. (1994). Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer, 74(3), 872–877.PubMedCrossRef Noguchi, S., Aihara, T., Koyama, H., Motomura, K., Inaji, H., & Imaoka, S. (1994). Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer, 74(3), 872–877.PubMedCrossRef
14.
Zurück zum Zitat Kreike, B., Hart, A. A., van de Velde, T., Borger, J., Peterse, H., Rutgers, E., et al. (2008). Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. International Journal of Radiation Oncology, Biology, Physics, 71(4), 1014–1021. doi:10.1016/j.ijrobp.2007.11.029.PubMedCrossRef Kreike, B., Hart, A. A., van de Velde, T., Borger, J., Peterse, H., Rutgers, E., et al. (2008). Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. International Journal of Radiation Oncology, Biology, Physics, 71(4), 1014–1021. doi:10.​1016/​j.​ijrobp.​2007.​11.​029.PubMedCrossRef
15.
Zurück zum Zitat Fisher, B., Anderson, S., Fisher, E. R., Redmond, C., Wickerham, D. L., Wolmark, N., et al. (1991). Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet, 338(8763), 327–331.PubMedCrossRef Fisher, B., Anderson, S., Fisher, E. R., Redmond, C., Wickerham, D. L., Wolmark, N., et al. (1991). Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet, 338(8763), 327–331.PubMedCrossRef
16.
18.
Zurück zum Zitat Coombs, N. J., & Boyages, J. (2005). Multifocal and multicentric breast cancer: Does each focus matter? Journal of Clinical Oncology, 23(30), 7497–7502.PubMedCrossRef Coombs, N. J., & Boyages, J. (2005). Multifocal and multicentric breast cancer: Does each focus matter? Journal of Clinical Oncology, 23(30), 7497–7502.PubMedCrossRef
19.
Zurück zum Zitat Andea, A. A., Bouwman, D., Wallis, T., & Visscher, D. W. (2004). Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer, 100(1), 20–27. doi:10.1002/cncr.11880.PubMedCrossRef Andea, A. A., Bouwman, D., Wallis, T., & Visscher, D. W. (2004). Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer, 100(1), 20–27. doi:10.​1002/​cncr.​11880.PubMedCrossRef
20.
Zurück zum Zitat Veronesi, U., Gatti, G., Luini, A., Intra, M., Ciocca, M., Sanchez, D., et al. (2003). Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery. Archives of Surgery, 138(11), 1253–1256.PubMedCrossRef Veronesi, U., Gatti, G., Luini, A., Intra, M., Ciocca, M., Sanchez, D., et al. (2003). Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery. Archives of Surgery, 138(11), 1253–1256.PubMedCrossRef
21.
Zurück zum Zitat Bernier, J., Viale, G., Orecchia, R., Ballardini, B., Richetti, A., Bronz, L., et al. (2006). Partial irradiation of the breast: old challenges, new solutions. Breast, 15(4), 466–475.PubMedCrossRef Bernier, J., Viale, G., Orecchia, R., Ballardini, B., Richetti, A., Bronz, L., et al. (2006). Partial irradiation of the breast: old challenges, new solutions. Breast, 15(4), 466–475.PubMedCrossRef
22.
Zurück zum Zitat Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., et al. (2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (targit-a trial): An international, prospective, randomised, non-inferiority phase 3 trial. Lancet, 376(9735), 91–102.PubMedCrossRef Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., et al. (2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (targit-a trial): An international, prospective, randomised, non-inferiority phase 3 trial. Lancet, 376(9735), 91–102.PubMedCrossRef
23.
Zurück zum Zitat Bartelink, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., et al. (2001). Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. The New England Journal of Medicine, 345(19), 1378–1387.PubMedCrossRef Bartelink, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., et al. (2001). Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. The New England Journal of Medicine, 345(19), 1378–1387.PubMedCrossRef
24.
Zurück zum Zitat Holland, R., Veling, S. H., Mravunac, M., & Hendriks, J. H. (1985). Histologic multifocality of tis, t1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer, 56(5), 979–990.PubMedCrossRef Holland, R., Veling, S. H., Mravunac, M., & Hendriks, J. H. (1985). Histologic multifocality of tis, t1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer, 56(5), 979–990.PubMedCrossRef
25.
Zurück zum Zitat Recht, A., Silen, W., Schnitt, S. J., Connolly, J. L., Gelman, R. S., Rose, M. A., et al. (1988). Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. International Journal of Radiation Oncology, Biology, Physics, 15(2), 255–261.PubMedCrossRef Recht, A., Silen, W., Schnitt, S. J., Connolly, J. L., Gelman, R. S., Rose, M. A., et al. (1988). Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. International Journal of Radiation Oncology, Biology, Physics, 15(2), 255–261.PubMedCrossRef
26.
Zurück zum Zitat Kurtz, J. M., Amalric, R., Brandone, H., Ayme, Y., & Spitalier, J. M. (1989). Local recurrence after breast-conserving surgery and radiotherapy. Helvetica Chirurgica Acta, 55(6), 837–842.PubMed Kurtz, J. M., Amalric, R., Brandone, H., Ayme, Y., & Spitalier, J. M. (1989). Local recurrence after breast-conserving surgery and radiotherapy. Helvetica Chirurgica Acta, 55(6), 837–842.PubMed
27.
Zurück zum Zitat Wise, A. M., Stamey, T. A., McNeal, J. E., & Clayton, J. L. (2002). Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology, 60(2), 264–269. doi:S0090429502017284.PubMedCrossRef Wise, A. M., Stamey, T. A., McNeal, J. E., & Clayton, J. L. (2002). Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology, 60(2), 264–269. doi:S009042950201728​4.PubMedCrossRef
29.
Zurück zum Zitat Holland, R., Connolly, J. L., Gelman, R., Mravunac, M., Hendriks, J. H., Verbeek, A. L., et al. (1990). The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. Journal of Clinical Oncology, 8(1), 113–118.PubMed Holland, R., Connolly, J. L., Gelman, R., Mravunac, M., Hendriks, J. H., Verbeek, A. L., et al. (1990). The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. Journal of Clinical Oncology, 8(1), 113–118.PubMed
30.
Zurück zum Zitat Kreike, B., Halfwerk, H., Armstrong, N., Bult, P., Foekens, J. A., Veltkamp, S. C., et al. (2009). Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clinical Cancer Research, 15(12), 4181–4190. doi:1078-0432.CCR-08-2644.PubMedCrossRef Kreike, B., Halfwerk, H., Armstrong, N., Bult, P., Foekens, J. A., Veltkamp, S. C., et al. (2009). Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clinical Cancer Research, 15(12), 4181–4190. doi:1078-0432.​CCR-08-2644.PubMedCrossRef
31.
Zurück zum Zitat Voogd, A. C., Peterse, J. L., Crommelin, M. A., Rutgers, E. J., Botke, G., Elkhuizen, P. H., et al. (1999). Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on Local Recurrence After Breast Conservation (BORST). European Journal of Cancer, 35(13), 1828–1837.PubMedCrossRef Voogd, A. C., Peterse, J. L., Crommelin, M. A., Rutgers, E. J., Botke, G., Elkhuizen, P. H., et al. (1999). Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on Local Recurrence After Breast Conservation (BORST). European Journal of Cancer, 35(13), 1828–1837.PubMedCrossRef
32.
Zurück zum Zitat Fredriksson, I., Liljegren, G., Palm-Sjovall, M., Arnesson, L. G., Emdin, S. O., Fornander, T., et al. (2003). Risk factors for local recurrence after breast-conserving surgery. The British Journal of Surgery, 90(9), 1093–1102. doi:10.1002/bjs.4206.PubMedCrossRef Fredriksson, I., Liljegren, G., Palm-Sjovall, M., Arnesson, L. G., Emdin, S. O., Fornander, T., et al. (2003). Risk factors for local recurrence after breast-conserving surgery. The British Journal of Surgery, 90(9), 1093–1102. doi:10.​1002/​bjs.​4206.PubMedCrossRef
33.
Zurück zum Zitat Hill-Kayser, C. E., Harris, E. E., Hwang, W. T., & Solin, L. J. (2006). Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. International Journal of Radiation Oncology, Biology, Physics, 66(5), 1313–1319.PubMedCrossRef Hill-Kayser, C. E., Harris, E. E., Hwang, W. T., & Solin, L. J. (2006). Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. International Journal of Radiation Oncology, Biology, Physics, 66(5), 1313–1319.PubMedCrossRef
34.
Zurück zum Zitat Oh, J. L., Dryden, M. J., Woodward, W. A., Yu, T. K., Tereffe, W., Strom, E. A., et al. (2006). Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. Journal of Clinical Oncology, 24(31), 4971–4975.PubMedCrossRef Oh, J. L., Dryden, M. J., Woodward, W. A., Yu, T. K., Tereffe, W., Strom, E. A., et al. (2006). Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. Journal of Clinical Oncology, 24(31), 4971–4975.PubMedCrossRef
35.
Zurück zum Zitat Gentilini, O., Botteri, E., Rotmensz, N., Da Lima, L., Caliskan, M., Garcia-Etienne, C. A., et al. (2009). Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Research and Treatment, 113(3), 577–583. doi:10.1007/s10549-008-9959-7.PubMedCrossRef Gentilini, O., Botteri, E., Rotmensz, N., Da Lima, L., Caliskan, M., Garcia-Etienne, C. A., et al. (2009). Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Research and Treatment, 113(3), 577–583. doi:10.​1007/​s10549-008-9959-7.PubMedCrossRef
36.
Zurück zum Zitat Houssami, N., Ciatto, S., Macaskill, P., Lord, S. J., Warren, R. M., Dixon, J. M., et al. (2008). Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. Journal of Clinical Oncology, 26(19), 3248–3258.PubMedCrossRef Houssami, N., Ciatto, S., Macaskill, P., Lord, S. J., Warren, R. M., Dixon, J. M., et al. (2008). Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. Journal of Clinical Oncology, 26(19), 3248–3258.PubMedCrossRef
37.
Zurück zum Zitat Lehman, C. D., Gatsonis, C., Kuhl, C. K., Hendrick, R. E., Pisano, E. D., Hanna, L., et al. (2007). Mri evaluation of the contralateral breast in women with recently diagnosed breast cancer. The New England Journal of Medicine, 356(13), 1295–1303. doi:NEJMoa065447.PubMedCrossRef Lehman, C. D., Gatsonis, C., Kuhl, C. K., Hendrick, R. E., Pisano, E. D., Hanna, L., et al. (2007). Mri evaluation of the contralateral breast in women with recently diagnosed breast cancer. The New England Journal of Medicine, 356(13), 1295–1303. doi:NEJMoa065447.PubMedCrossRef
38.
Zurück zum Zitat Sardanelli, F., Giuseppetti, G. M., Panizza, P., Bazzocchi, M., Fausto, A., Simonetti, G., et al. (2004). Sensitivity of mri versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR. American Journal of Roentgenology, 183(4), 1149–1157.PubMed Sardanelli, F., Giuseppetti, G. M., Panizza, P., Bazzocchi, M., Fausto, A., Simonetti, G., et al. (2004). Sensitivity of mri versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR. American Journal of Roentgenology, 183(4), 1149–1157.PubMed
39.
Zurück zum Zitat Peer, P. G., van Dijck, J. A., Hendriks, J. H., Holland, R., & Verbeek, A. L. (1993). Age-dependent growth rate of primary breast cancer. Cancer, 71(11), 3547–3551.PubMedCrossRef Peer, P. G., van Dijck, J. A., Hendriks, J. H., Holland, R., & Verbeek, A. L. (1993). Age-dependent growth rate of primary breast cancer. Cancer, 71(11), 3547–3551.PubMedCrossRef
40.
Zurück zum Zitat Kuroishi, T., Tominaga, S., Morimoto, T., Tashiro, H., Itoh, S., Watanabe, H., et al. (1990). Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Japanese Journal of Cancer Research, 81(5), 454–462.PubMed Kuroishi, T., Tominaga, S., Morimoto, T., Tashiro, H., Itoh, S., Watanabe, H., et al. (1990). Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Japanese Journal of Cancer Research, 81(5), 454–462.PubMed
41.
Zurück zum Zitat Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., et al. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. The New England Journal of Medicine, 347(16), 1233–1241. doi:10.1056/NEJMoa022152.PubMedCrossRef Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., et al. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. The New England Journal of Medicine, 347(16), 1233–1241. doi:10.​1056/​NEJMoa022152.PubMedCrossRef
42.
Zurück zum Zitat Husemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58–68. doi:S1535-6108(07)00372-8.PubMedCrossRef Husemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58–68. doi:S1535-6108(07)00372-8.PubMedCrossRef
43.
Zurück zum Zitat Klein, C. A., & Hölzel, D. (2006). Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle, 5(16), 1788–1798. doi:3097.PubMedCrossRef Klein, C. A., & Hölzel, D. (2006). Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle, 5(16), 1788–1798. doi:3097.PubMedCrossRef
44.
Zurück zum Zitat Engel, J., Eckel, R., Kerr, J., Schmidt, M., Furstenberger, G., Richter, R., et al. (2003). The process of metastasisation for breast cancer. European Journal of Cancer, 39(12), 1794–1806. doi:S0959804903004222.PubMedCrossRef Engel, J., Eckel, R., Kerr, J., Schmidt, M., Furstenberger, G., Richter, R., et al. (2003). The process of metastasisation for breast cancer. European Journal of Cancer, 39(12), 1794–1806. doi:S095980490300422​2.PubMedCrossRef
45.
Zurück zum Zitat Fisher, B., & Anderson, S. J. (2010). The breast cancer alternative hypothesis: Is there evidence to justify replacing it? Journal of Clinical Oncology, 28(3), 366–374. doi:JCO.2009.26.8292.PubMedCrossRef Fisher, B., & Anderson, S. J. (2010). The breast cancer alternative hypothesis: Is there evidence to justify replacing it? Journal of Clinical Oncology, 28(3), 366–374. doi:JCO.​2009.​26.​8292.PubMedCrossRef
46.
Zurück zum Zitat Demicheli, R., Terenziani, M., & Bonadonna, G. (1998). Estimate of tumor growth time for breast cancer local recurrences: Rapid growth after wake-up? Breast Cancer Research and Treatment, 51(2), 133–137.PubMedCrossRef Demicheli, R., Terenziani, M., & Bonadonna, G. (1998). Estimate of tumor growth time for breast cancer local recurrences: Rapid growth after wake-up? Breast Cancer Research and Treatment, 51(2), 133–137.PubMedCrossRef
47.
Zurück zum Zitat Naumov, G. N., Akslen, L. A., & Folkman, J. (2006). Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle, 5(16), 1779–1787. doi:3018.PubMedCrossRef Naumov, G. N., Akslen, L. A., & Folkman, J. (2006). Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle, 5(16), 1779–1787. doi:3018.PubMedCrossRef
48.
Zurück zum Zitat Komoike, Y., Akiyama, F., Iino, Y., Ikeda, T., Akashi-Tanaka, S., Ohsumi, S., et al. (2006). Ipsilateral breast tumor recurrence (ibtr) after breast-conserving treatment for early breast cancer: Risk factors and impact on distant metastases. Cancer, 106(1), 35–41. doi:10.1002/cncr.21551.PubMedCrossRef Komoike, Y., Akiyama, F., Iino, Y., Ikeda, T., Akashi-Tanaka, S., Ohsumi, S., et al. (2006). Ipsilateral breast tumor recurrence (ibtr) after breast-conserving treatment for early breast cancer: Risk factors and impact on distant metastases. Cancer, 106(1), 35–41. doi:10.​1002/​cncr.​21551.PubMedCrossRef
49.
Zurück zum Zitat Zahl, P. H., Maehlen, J., & Welch, H. G. (2008). The natural history of invasive breast cancers detected by screening mammography. Archives of Internal Medicine, 168(21), 2311–2316. doi:168/21/2311.PubMedCrossRef Zahl, P. H., Maehlen, J., & Welch, H. G. (2008). The natural history of invasive breast cancers detected by screening mammography. Archives of Internal Medicine, 168(21), 2311–2316. doi:168/​21/​2311.PubMedCrossRef
50.
Zurück zum Zitat Bories, N., Dalle, S., Debarbieux, S., Balme, B., Ronger-Savle, S., & Thomas, L. (2008). Dermoscopy of fully regressive cutaneous melanoma. The British Journal of Dermatology, 158(6), 1224–1229. doi:BJD8501.PubMedCrossRef Bories, N., Dalle, S., Debarbieux, S., Balme, B., Ronger-Savle, S., & Thomas, L. (2008). Dermoscopy of fully regressive cutaneous melanoma. The British Journal of Dermatology, 158(6), 1224–1229. doi:BJD8501.PubMedCrossRef
51.
Zurück zum Zitat Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., et al. (2009). Breast cancer after use of estrogen plus progestin in postmenopausal women. The New England Journal of Medicine, 360(6), 573–587. doi:360/6/573.PubMedCrossRef Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., et al. (2009). Breast cancer after use of estrogen plus progestin in postmenopausal women. The New England Journal of Medicine, 360(6), 573–587. doi:360/​6/​573.PubMedCrossRef
52.
Zurück zum Zitat Perry, N., Broeders, M., de Wolf, C., Tornberg, S., Holland, R., & von Karsa, L. (2008). European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition—summary document. Annals of Oncology, 19(4), 614–622. doi:mdm481.PubMedCrossRef Perry, N., Broeders, M., de Wolf, C., Tornberg, S., Holland, R., & von Karsa, L. (2008). European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition—summary document. Annals of Oncology, 19(4), 614–622. doi:mdm481.PubMedCrossRef
53.
Zurück zum Zitat Jorgensen, K. J., & Gotzsche, P. C. (2009). Overdiagnosis in publicly organised mammography screening programmes: Systematic review of incidence trends. British Medical Journal, 339, b2587.PubMedCrossRef Jorgensen, K. J., & Gotzsche, P. C. (2009). Overdiagnosis in publicly organised mammography screening programmes: Systematic review of incidence trends. British Medical Journal, 339, b2587.PubMedCrossRef
54.
Zurück zum Zitat Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., et al. (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol b-27. Journal of Clinical Oncology, 21(22), 4165–4174. doi:10.1200/JCO.2003.12.005.PubMedCrossRef Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., et al. (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol b-27. Journal of Clinical Oncology, 21(22), 4165–4174. doi:10.​1200/​JCO.​2003.​12.​005.PubMedCrossRef
55.
Zurück zum Zitat Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., et al. (2008). Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols b-18 and b-27. Journal of Clinical Oncology, 26(5), 778–785. doi:26/5/778.PubMedCrossRef Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., et al. (2008). Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols b-18 and b-27. Journal of Clinical Oncology, 26(5), 778–785. doi:26/​5/​778.PubMedCrossRef
56.
Zurück zum Zitat Phillips, T. M., McBride, W. H., & Pajonk, F. (2006). The response of cd24(−/low)/cd44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute, 98(24), 1777–1785. doi:98/24/1777.PubMedCrossRef Phillips, T. M., McBride, W. H., & Pajonk, F. (2006). The response of cd24(−/low)/cd44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute, 98(24), 1777–1785. doi:98/​24/​1777.PubMedCrossRef
57.
Zurück zum Zitat Joergensen, L. E., Gunnarsdottir, K. A., Lanng, C., Moeller, S., & Rasmussen, B. B. (2008). Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996–2001. Breast, 17(6), 587–591. doi:S0960-9776(08)00153-7.PubMedCrossRef Joergensen, L. E., Gunnarsdottir, K. A., Lanng, C., Moeller, S., & Rasmussen, B. B. (2008). Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996–2001. Breast, 17(6), 587–591. doi:S0960-9776(08)00153-7.PubMedCrossRef
58.
Zurück zum Zitat Yerushalmi, R., Kennecke, H., Woods, R., Olivotto, I. A., Speers, C., & Gelmon, K. A. (2008). Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Research and Treatment. doi:10.1007/s10549-008-0265-1.PubMed Yerushalmi, R., Kennecke, H., Woods, R., Olivotto, I. A., Speers, C., & Gelmon, K. A. (2008). Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Research and Treatment. doi:10.​1007/​s10549-008-0265-1.PubMed
59.
Zurück zum Zitat Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., et al. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. The New England Journal of Medicine, 347(16), 1227–1232. doi:10.1056/NEJMoa020989.PubMedCrossRef Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., et al. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. The New England Journal of Medicine, 347(16), 1227–1232. doi:10.​1056/​NEJMoa020989.PubMedCrossRef
60.
Zurück zum Zitat van Dongen, J. A., Voogd, A. C., Fentiman, I. S., Legrand, C., Sylvester, R. J., Tong, D., et al. (2000). Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. Journal of the National Cancer Institute, 92(14), 1143–1150.PubMedCrossRef van Dongen, J. A., Voogd, A. C., Fentiman, I. S., Legrand, C., Sylvester, R. J., Tong, D., et al. (2000). Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. Journal of the National Cancer Institute, 92(14), 1143–1150.PubMedCrossRef
61.
Zurück zum Zitat Sobin, L., Gospodarowicz, M., & Wittekind, C. (Eds.). (2009). UICC: TNM classification of malignant tumors (7th ed.). UK: Wiley-Blackwell. Sobin, L., Gospodarowicz, M., & Wittekind, C. (Eds.). (2009). UICC: TNM classification of malignant tumors (7th ed.). UK: Wiley-Blackwell.
62.
Zurück zum Zitat Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J. H., et al. (2009). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. Journal of Clinical Oncology, 27(15), 2466–2473. doi:JCO.2008.19.8424.PubMedCrossRef Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J. H., et al. (2009). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. Journal of Clinical Oncology, 27(15), 2466–2473. doi:JCO.​2008.​19.​8424.PubMedCrossRef
63.
Zurück zum Zitat de Bock, G. H., van der Hage, J. A., Putter, H., Bonnema, J., Bartelink, H., & van de Velde, C. J. (2006). Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer Studies. European Journal of Cancer, 42(3), 351–356. doi:S0959-8049(05)00893-2.PubMedCrossRef de Bock, G. H., van der Hage, J. A., Putter, H., Bonnema, J., Bartelink, H., & van de Velde, C. J. (2006). Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer Studies. European Journal of Cancer, 42(3), 351–356. doi:S0959-8049(05)00893-2.PubMedCrossRef
64.
Zurück zum Zitat Jones, H. A., Antonini, N., Hart, A. A., Peterse, J. L., Horiot, J. C., Collin, F., et al. (2009). Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. Journal of Clinical Oncology. doi:JCO.2008.21.5764. Jones, H. A., Antonini, N., Hart, A. A., Peterse, J. L., Horiot, J. C., Collin, F., et al. (2009). Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. Journal of Clinical Oncology. doi:JCO.​2008.​21.​5764.
65.
Zurück zum Zitat Vicini, F. A., Kestin, L., Huang, R., & Martinez, A. (2003). Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer, 97(4), 910–919.PubMedCrossRef Vicini, F. A., Kestin, L., Huang, R., & Martinez, A. (2003). Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer, 97(4), 910–919.PubMedCrossRef
66.
Zurück zum Zitat de Bock, G. H., Putter, H., Bonnema, J., van der Hage, J. A., Bartelink, H., & van de Velde, C. J. (2009). The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: A multistate model. Breast Cancer Research and Treatment, 117(2), 401–408. doi:10.1007/s10549-008-0300-2.PubMedCrossRef de Bock, G. H., Putter, H., Bonnema, J., van der Hage, J. A., Bartelink, H., & van de Velde, C. J. (2009). The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: A multistate model. Breast Cancer Research and Treatment, 117(2), 401–408. doi:10.​1007/​s10549-008-0300-2.PubMedCrossRef
67.
Zurück zum Zitat Gujral, D. M., Sumo, G., Owen, J. R., Ashton, A., Bliss, J. M., Haviland, J., et al. (2011). Ipsilateral breast tumor relapse: Local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries. International Journal of Radiation Oncology, Biology, Physics, 79(1), 19–25.PubMedCrossRef Gujral, D. M., Sumo, G., Owen, J. R., Ashton, A., Bliss, J. M., Haviland, J., et al. (2011). Ipsilateral breast tumor relapse: Local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries. International Journal of Radiation Oncology, Biology, Physics, 79(1), 19–25.PubMedCrossRef
68.
Zurück zum Zitat Vicini, F. A., Antonucci, J. V., Wallace, M., Gilbert, S., Goldstein, N. S., Kestin, L., et al. (2007). Long-term efficacy and patterns of failure after accelerated partial breast irradiation: A molecular assay-based clonality evaluation. International Journal of Radiation Oncology, Biology, Physics, 68(2), 341–346. doi:S0360-3016(06)03636-4.PubMedCrossRef Vicini, F. A., Antonucci, J. V., Wallace, M., Gilbert, S., Goldstein, N. S., Kestin, L., et al. (2007). Long-term efficacy and patterns of failure after accelerated partial breast irradiation: A molecular assay-based clonality evaluation. International Journal of Radiation Oncology, Biology, Physics, 68(2), 341–346. doi:S0360-3016(06)03636-4.PubMedCrossRef
69.
Zurück zum Zitat Whipp, E., Beresford, M., Sawyer, E., & Halliwell, M. (2010). True local recurrence rate in the conserved breast after magnetic resonance imaging-targeted radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 76(4), 984–990.PubMedCrossRef Whipp, E., Beresford, M., Sawyer, E., & Halliwell, M. (2010). True local recurrence rate in the conserved breast after magnetic resonance imaging-targeted radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 76(4), 984–990.PubMedCrossRef
70.
Zurück zum Zitat Wapnir, I. L., Anderson, S. J., Mamounas, E. P., Geyer, C. E., Jr., Jeong, J. H., Tan-Chiu, E., et al. (2006). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. Journal of Clinical Oncology, 24(13), 2028–2037. doi:24/13/2028.PubMedCrossRef Wapnir, I. L., Anderson, S. J., Mamounas, E. P., Geyer, C. E., Jr., Jeong, J. H., Tan-Chiu, E., et al. (2006). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. Journal of Clinical Oncology, 24(13), 2028–2037. doi:24/​13/​2028.PubMedCrossRef
71.
Zurück zum Zitat Cheng, L., Song, S. Y., Pretlow, T. G., Abdul-Karim, F. W., Kung, H. J., Dawson, D. V., et al. (1998). Evidence of independent origin of multiple tumors from patients with prostate cancer. Journal of the National Cancer Institute, 90(3), 233–237.PubMedCrossRef Cheng, L., Song, S. Y., Pretlow, T. G., Abdul-Karim, F. W., Kung, H. J., Dawson, D. V., et al. (1998). Evidence of independent origin of multiple tumors from patients with prostate cancer. Journal of the National Cancer Institute, 90(3), 233–237.PubMedCrossRef
72.
Zurück zum Zitat Johnson, B. E., Cortazar, P., & Chute, J. P. (1997). Second lung cancers in patients successfully treated for lung cancer. Seminars in Oncology, 24(4), 492–499.PubMed Johnson, B. E., Cortazar, P., & Chute, J. P. (1997). Second lung cancers in patients successfully treated for lung cancer. Seminars in Oncology, 24(4), 492–499.PubMed
73.
Zurück zum Zitat Machens, A., Hauptmann, S., & Dralle, H. (2007). Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World Journal of Surgery, 31(10), 1960–1965. doi:10.1007/s00268-007-9185-1.PubMedCrossRef Machens, A., Hauptmann, S., & Dralle, H. (2007). Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World Journal of Surgery, 31(10), 1960–1965. doi:10.​1007/​s00268-007-9185-1.PubMedCrossRef
74.
Zurück zum Zitat Jensen, A. R., Nellemann, H. M., & Overgaard, J. (2007). Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiotherapy and Oncology, 84(1), 5–10. doi:S0167-8140(07)00153-3.PubMedCrossRef Jensen, A. R., Nellemann, H. M., & Overgaard, J. (2007). Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiotherapy and Oncology, 84(1), 5–10. doi:S0167-8140(07)00153-3.PubMedCrossRef
75.
Zurück zum Zitat Belt, E. J., van Stijn, M. F., Bril, H., de Lange-de Klerk, E. S., Meijer, G. A., Meijer, S., et al. (2010). Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III. Annals of Surgical Oncology, 17(12), 3203–3211.PubMedCrossRef Belt, E. J., van Stijn, M. F., Bril, H., de Lange-de Klerk, E. S., Meijer, G. A., Meijer, S., et al. (2010). Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III. Annals of Surgical Oncology, 17(12), 3203–3211.PubMedCrossRef
76.
Zurück zum Zitat Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R., et al. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England Journal of Medicine, 351(17), 1731–1740. doi:351/17/1731.PubMedCrossRef Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R., et al. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England Journal of Medicine, 351(17), 1731–1740. doi:351/​17/​1731.PubMedCrossRef
77.
Zurück zum Zitat Camma, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxi, A., & Cottone, M. (2000). Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Journal of the American Medical Association, 284(8), 1008–1015. doi:jma00002.PubMedCrossRef Camma, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxi, A., & Cottone, M. (2000). Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Journal of the American Medical Association, 284(8), 1008–1015. doi:jma00002.PubMedCrossRef
78.
Zurück zum Zitat O’Daly, B. J., Sweeney, K. J., Ridgway, P. F., Quinn, C., McDermott, E. W., O’Higgins, N. J., et al. (2007). The accuracy of combined versus largest diameter in staging multifocal breast cancer. Journal of the American College of Surgeons, 204(2), 282–285.PubMedCrossRef O’Daly, B. J., Sweeney, K. J., Ridgway, P. F., Quinn, C., McDermott, E. W., O’Higgins, N. J., et al. (2007). The accuracy of combined versus largest diameter in staging multifocal breast cancer. Journal of the American College of Surgeons, 204(2), 282–285.PubMedCrossRef
79.
Zurück zum Zitat Nagtegaal, I. D., & Quirke, P. (2007). Colorectal tumour deposits in the mesorectum and pericolon; a critical review. Histopathology, 51(2), 141–149. doi:HIS2720.PubMedCrossRef Nagtegaal, I. D., & Quirke, P. (2007). Colorectal tumour deposits in the mesorectum and pericolon; a critical review. Histopathology, 51(2), 141–149. doi:HIS2720.PubMedCrossRef
80.
Zurück zum Zitat Tresserra, F., Rodriguez, I., Garcia-Yuste, M., Grases, P. J., Ara, C., & Fabregas, R. (2007). Tumor size and lymph node status in multifocal breast cancer. The Breast Journal, 13(1), 68–71.PubMedCrossRef Tresserra, F., Rodriguez, I., Garcia-Yuste, M., Grases, P. J., Ara, C., & Fabregas, R. (2007). Tumor size and lymph node status in multifocal breast cancer. The Breast Journal, 13(1), 68–71.PubMedCrossRef
81.
Zurück zum Zitat Slaughter, D. P., Southwick, H. W., & Smejkal, W. (1953). Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 6(5), 963–968.PubMedCrossRef Slaughter, D. P., Southwick, H. W., & Smejkal, W. (1953). Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 6(5), 963–968.PubMedCrossRef
82.
Zurück zum Zitat Braakhuis, B. J., Tabor, M. P., Kummer, J. A., Leemans, C. R., & Brakenhoff, R. H. (2003). A genetic explanation of slaughter’s concept of field cancerization: Evidence and clinical implications. Cancer Research, 63(8), 1727–1730.PubMed Braakhuis, B. J., Tabor, M. P., Kummer, J. A., Leemans, C. R., & Brakenhoff, R. H. (2003). A genetic explanation of slaughter’s concept of field cancerization: Evidence and clinical implications. Cancer Research, 63(8), 1727–1730.PubMed
84.
Zurück zum Zitat Dakubo, G. D., Jakupciak, J. P., Birch-Machin, M. A., & Parr, R. L. (2007). Clinical implications and utility of field cancerization. Cancer Cell International, 7, 2. doi:1475-2867-7-2.PubMedCrossRef Dakubo, G. D., Jakupciak, J. P., Birch-Machin, M. A., & Parr, R. L. (2007). Clinical implications and utility of field cancerization. Cancer Cell International, 7, 2. doi:1475-2867-7-2.PubMedCrossRef
85.
Zurück zum Zitat Utsunomiya, T., Shimada, M., Imura, S., Morine, Y., Ikemoto, T., & Mori, M. (2010). Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. Journal of Gastroenterology, 45(2), 146–152.PubMedCrossRef Utsunomiya, T., Shimada, M., Imura, S., Morine, Y., Ikemoto, T., & Mori, M. (2010). Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. Journal of Gastroenterology, 45(2), 146–152.PubMedCrossRef
86.
Zurück zum Zitat Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994). Mortality in relation to smoking: 40 years’ observations on male british doctors. British Medical Journal, 309(6959), 901–911.PubMed Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994). Mortality in relation to smoking: 40 years’ observations on male british doctors. British Medical Journal, 309(6959), 901–911.PubMed
87.
Zurück zum Zitat Wang, X., Wang, M., MacLennan, G. T., Abdul-Karim, F. W., Eble, J. N., Jones, T. D., et al. (2009). Evidence for common clonal origin of multifocal lung cancers. Journal of the National Cancer Institute, 101(8), 560–570. doi:djp054.PubMedCrossRef Wang, X., Wang, M., MacLennan, G. T., Abdul-Karim, F. W., Eble, J. N., Jones, T. D., et al. (2009). Evidence for common clonal origin of multifocal lung cancers. Journal of the National Cancer Institute, 101(8), 560–570. doi:djp054.PubMedCrossRef
88.
Zurück zum Zitat Gazdar, A. F., & Minna, J. D. (2009). Multifocal lung cancers—clonality vs. field cancerization and does it matter? Journal of the National Cancer Institute, 101(8), 541–543. doi:djp059.PubMedCrossRef Gazdar, A. F., & Minna, J. D. (2009). Multifocal lung cancers—clonality vs. field cancerization and does it matter? Journal of the National Cancer Institute, 101(8), 541–543. doi:djp059.PubMedCrossRef
89.
Zurück zum Zitat Shimizu, S., Yatabe, Y., Koshikawa, T., Haruki, N., Hatooka, S., Shinoda, M., et al. (2000). High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clinical Cancer Research, 6(10), 3994–3999.PubMed Shimizu, S., Yatabe, Y., Koshikawa, T., Haruki, N., Hatooka, S., Shinoda, M., et al. (2000). High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clinical Cancer Research, 6(10), 3994–3999.PubMed
90.
Zurück zum Zitat Riquet, M., Cazes, A., Pfeuty, K., Ngabou, U. D., Foucault, C., Dujon, A., et al. (2008). Multiple lung cancers prognosis: What about histology? The Annals of Thoracic Surgery, 86(3), 921–926. doi:S0003-4975(08)01119-3.PubMedCrossRef Riquet, M., Cazes, A., Pfeuty, K., Ngabou, U. D., Foucault, C., Dujon, A., et al. (2008). Multiple lung cancers prognosis: What about histology? The Annals of Thoracic Surgery, 86(3), 921–926. doi:S0003-4975(08)01119-3.PubMedCrossRef
91.
Zurück zum Zitat Fisher, B., Land, S., Mamounas, E., Dignam, J., Fisher, E. R., & Wolmark, N. (2001). Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Seminars in Oncology, 28(4), 400–418. doi:S0093775401001531.PubMedCrossRef Fisher, B., Land, S., Mamounas, E., Dignam, J., Fisher, E. R., & Wolmark, N. (2001). Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Seminars in Oncology, 28(4), 400–418. doi:S009377540100153​1.PubMedCrossRef
92.
Zurück zum Zitat Houghton, J., George, W. D., Cuzick, J., Duggan, C., Fentiman, I. S., & Spittle, M. (2003). Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet, 362(9378), 95–102. doi:S0140673603138597.PubMedCrossRef Houghton, J., George, W. D., Cuzick, J., Duggan, C., Fentiman, I. S., & Spittle, M. (2003). Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet, 362(9378), 95–102. doi:S014067360313859​7.PubMedCrossRef
93.
Zurück zum Zitat Bijker, N., Meijnen, P., Peterse, J. L., Bogaerts, J., Van Hoorebeeck, I., Julien, J. P., et al. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of Clinical Oncology, 24(21), 3381–3387. doi:JCO.2006.06.1366.PubMedCrossRef Bijker, N., Meijnen, P., Peterse, J. L., Bogaerts, J., Van Hoorebeeck, I., Julien, J. P., et al. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of Clinical Oncology, 24(21), 3381–3387. doi:JCO.​2006.​06.​1366.PubMedCrossRef
94.
Zurück zum Zitat Page, D. L., Dupont, W. D., Rogers, L. W., Jensen, R. A., & Schuyler, P. A. (1995). Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer, 76(7), 1197–1200.PubMedCrossRef Page, D. L., Dupont, W. D., Rogers, L. W., Jensen, R. A., & Schuyler, P. A. (1995). Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer, 76(7), 1197–1200.PubMedCrossRef
95.
Zurück zum Zitat Guerra, L. E., Smith, R. M., Kaminski, A., Lagios, M. D., & Silverstein, M. J. (2008). Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ. American Journal of Surgery, 196(4), 552–555. doi:S0002-9610(08)00457-1.PubMedCrossRef Guerra, L. E., Smith, R. M., Kaminski, A., Lagios, M. D., & Silverstein, M. J. (2008). Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ. American Journal of Surgery, 196(4), 552–555. doi:S0002-9610(08)00457-1.PubMedCrossRef
96.
Zurück zum Zitat Glaves, D., Huben, R. P., & Weiss, L. (1988). Haematogenous dissemination of cells from human renal adenocarcinomas. British Journal of Cancer, 57(1), 32–35.PubMedCrossRef Glaves, D., Huben, R. P., & Weiss, L. (1988). Haematogenous dissemination of cells from human renal adenocarcinomas. British Journal of Cancer, 57(1), 32–35.PubMedCrossRef
97.
Zurück zum Zitat Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews. Cancer, 9(4), 302–312. doi:nrc2627.PubMedCrossRef Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews. Cancer, 9(4), 302–312. doi:nrc2627.PubMedCrossRef
99.
Zurück zum Zitat Cheng, L., Jones, T. D., Pan, C. X., Barbarin, A., Eble, J. N., & Koch, M. O. (2005). Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Modern Pathology, 18(8), 1022–1026. doi:3800431.PubMedCrossRef Cheng, L., Jones, T. D., Pan, C. X., Barbarin, A., Eble, J. N., & Koch, M. O. (2005). Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Modern Pathology, 18(8), 1022–1026. doi:3800431.PubMedCrossRef
100.
Zurück zum Zitat Landthaler, M., Braun-Falco, O., Leitl, A., Konz, B., & Holzel, D. (1989). Excisional biopsy as the first therapeutic procedure versus primary wide excision of malignant melanoma. Cancer, 64(8), 1612–1616.PubMedCrossRef Landthaler, M., Braun-Falco, O., Leitl, A., Konz, B., & Holzel, D. (1989). Excisional biopsy as the first therapeutic procedure versus primary wide excision of malignant melanoma. Cancer, 64(8), 1612–1616.PubMedCrossRef
101.
Zurück zum Zitat Weyers, W. (1997). Excision of melanoma in historical perspective: Triumph of irrationality for nearly a century. Dermatopathology, 3, 238–246. Weyers, W. (1997). Excision of melanoma in historical perspective: Triumph of irrationality for nearly a century. Dermatopathology, 3, 238–246.
102.
Zurück zum Zitat Thompson, I. M., Jr., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., et al. (2006). Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. Journal of the American Medical Association, 296(19), 2329–2335. doi:296/19/2329.PubMedCrossRef Thompson, I. M., Jr., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., et al. (2006). Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. Journal of the American Medical Association, 296(19), 2329–2335. doi:296/​19/​2329.PubMedCrossRef
103.
Zurück zum Zitat Bolla, M., van Poppel, H., Collette, L., van Cangh, P., Vekemans, K., Da Pozzo, L., et al. (2005). Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet, 366(9485), 572–578. doi:S0140-6736(05)67101-2.PubMedCrossRef Bolla, M., van Poppel, H., Collette, L., van Cangh, P., Vekemans, K., Da Pozzo, L., et al. (2005). Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet, 366(9485), 572–578. doi:S0140-6736(05)67101-2.PubMedCrossRef
104.
Zurück zum Zitat Gazdar, A. F. (2010). Epidermal growth factor receptor inhibition in lung cancer: The evolving role of individualized therapy. Cancer and Metastasis Reviews, 29(1), 37–48.PubMedCrossRef Gazdar, A. F. (2010). Epidermal growth factor receptor inhibition in lung cancer: The evolving role of individualized therapy. Cancer and Metastasis Reviews, 29(1), 37–48.PubMedCrossRef
105.
Zurück zum Zitat Heidenreich, A., Richter, S., Thuer, D., & Pfister, D. (2010). Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. European Urology, 57(3), 437–443.PubMedCrossRef Heidenreich, A., Richter, S., Thuer, D., & Pfister, D. (2010). Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. European Urology, 57(3), 437–443.PubMedCrossRef
106.
Zurück zum Zitat Trock, B. J., Han, M., Freedland, S. J., Humphreys, E. B., DeWeese, T. L., Partin, A. W., et al. (2008). Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Journal of the American Medical Association, 299(23), 2760–2769. doi:299/23/2760.PubMedCrossRef Trock, B. J., Han, M., Freedland, S. J., Humphreys, E. B., DeWeese, T. L., Partin, A. W., et al. (2008). Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Journal of the American Medical Association, 299(23), 2760–2769. doi:299/​23/​2760.PubMedCrossRef
107.
Zurück zum Zitat International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. (1995). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345(8955), 939–944.CrossRef International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. (1995). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345(8955), 939–944.CrossRef
109.
Zurück zum Zitat Swedish Rectal Cancer Trial. (1997). Improved survival with preoperative radiotherapy in resectable rectal cancer. New England Journal of Medicine, 336(14), 980–987.CrossRef Swedish Rectal Cancer Trial. (1997). Improved survival with preoperative radiotherapy in resectable rectal cancer. New England Journal of Medicine, 336(14), 980–987.CrossRef
111.
Zurück zum Zitat Camara, O., Rengsberger, M., Egbe, A., Koch, A., Gajda, M., Hammer, U., et al. (2007). The relevance of circulating epithelial tumor cells (cetc) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Annals of Oncology, 18(9), 1484–1492. doi:18/9/1484.PubMedCrossRef Camara, O., Rengsberger, M., Egbe, A., Koch, A., Gajda, M., Hammer, U., et al. (2007). The relevance of circulating epithelial tumor cells (cetc) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Annals of Oncology, 18(9), 1484–1492. doi:18/​9/​1484.PubMedCrossRef
112.
Zurück zum Zitat Pachmann, K., Camara, O., Kavallaris, A., Krauspe, S., Malarski, N., Gajda, M., et al. (2008). Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. Journal of Clinical Oncology, 26(8), 1208–1215. doi:26/8/1208.PubMedCrossRef Pachmann, K., Camara, O., Kavallaris, A., Krauspe, S., Malarski, N., Gajda, M., et al. (2008). Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. Journal of Clinical Oncology, 26(8), 1208–1215. doi:26/​8/​1208.PubMedCrossRef
113.
Zurück zum Zitat Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine, 351(8), 781–791. doi:10.1056/NEJMoa040766.PubMedCrossRef Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine, 351(8), 781–791. doi:10.​1056/​NEJMoa040766.PubMedCrossRef
114.
Zurück zum Zitat Nimeus-Malmstrom, E., Krogh, M., Malmstrom, P., Strand, C., Fredriksson, I., Karlsson, P., et al. (2008). Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Research, 10(2), R34.PubMedCrossRef Nimeus-Malmstrom, E., Krogh, M., Malmstrom, P., Strand, C., Fredriksson, I., Karlsson, P., et al. (2008). Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Research, 10(2), R34.PubMedCrossRef
115.
Zurück zum Zitat Punglia, R. S., Morrow, M., Winer, E. P., & Harris, J. R. (2007). Local therapy and survival in breast cancer. The New England Journal of Medicine, 356(23), 2399–2405. doi:356/23/2399.PubMedCrossRef Punglia, R. S., Morrow, M., Winer, E. P., & Harris, J. R. (2007). Local therapy and survival in breast cancer. The New England Journal of Medicine, 356(23), 2399–2405. doi:356/​23/​2399.PubMedCrossRef
Metadaten
Titel
True local recurrences do not metastasize
verfasst von
Dieter Hölzel
Rebecca T. Emeny
Jutta Engel
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2/2011
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9275-2

Weitere Artikel der Ausgabe 2/2011

Cancer and Metastasis Reviews 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.